Bookmark
Forward
QuickView for mecasermin (compound)
DrugBank
Identification
| Name: | myotrophin |
|---|---|
| Name (isomeric): | DB01277 |
| Drug Type: | biotech |
| Synonyms: |
Mecasermin rinfabate
|
| Brand: | Increlex, Iplex, Increlex (Tercica) |
| CAS number: | 68562-41-4 |
Pharmacology
| Indication: | For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy. |
|---|---|
| Pharmacology: |
Mecasermin is a biosynthetic (recombinant DNA origin) form of human insulin growth factor 1 (IGF-1) designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normalized statural growth. Growth hormones (GH) bind to growth hormone receptors (GHR) in the liver and other tissues, which stimulates the synthesis of IGF-1. In t...
show more » |
| Mechanism of Action: | Mecasermin supplies recombinant-DNA-origin IGF-1, which binds to the Type I IGF-1 receptor. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth. |
| Absorption: | While the bioavailability of rhIGF-1 after subcutaneous administration in healthy subjects has been reported to be close to 100%, the absolute bioavailability of mecasermin given subcutaneously to subjects with primary insulin-like growth factor-1 deficiency (Primary IGFD) has not been determined. |
| Protein binding: | In blood, IGF-1 is bound to six IGF binding proteins, with > 80% bound as a complex with IGFBP-3 and an acid-labile subunit. |
| Biotransformation: | Both the liver and the kidney have been shown to metabolize IGF-1. |
| Route of elimination: | Both the liver and the kidney have been shown to metabolize IGF-1. |
| Half Life: | 2 hours |
| Toxicity: | There is no clinical experience with overdosage of mecasermin. Based on known pharmacological effects, acute overdosage would be predicted to lead to hypoglycemia. Long-term overdosage may result in signs and symptoms of acromegaly. |
| Affected organisms: | Humans and other mammals |
Targets
